Search

Your search keyword '"A. Gomez De Iturriaga"' showing total 24 results
Start Over Author "A. Gomez De Iturriaga"
24 results on '"A. Gomez De Iturriaga"'

4. Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer

Author

A. Rodríguez, J. Pastor Peidro, J. Anchuelo, F. Ferrer, A. Gomez de Iturriaga, M. Rico, V. Morillo, Antonio J. Conde-Moreno, Asunción Hervás, Almudena Zapatero, Aniceto Mendez, J. Valero Albarran, Francisco J. López, P. Samper Ots, M.L. Vázquez de la Torre, L. A. Perez Romasanta, C. Ibañez, Carlos Ferrer Albiach, and M.D.M. Puertas

Subjects
Oncology, Biochemical recurrence, Cancer Research, Chemotherapy, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, medicine.disease, Androgen deprivation therapy, Prostate cancer, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, Concomitant, Internal medicine, medicine, Enzalutamide, Radiology, Nuclear Medicine and imaging, Stage (cooking), business, Lymph node
Abstract

Purpose/Objective(s) SBRT-SG 05 is a collaborative (SBRT-SG, GICOR and SEOR) prospective multicenter phase II trial testing SBRT and androgen deprivation therapy (ADT) in oligorecurrent prostate cancer patients. Materials/Methods Prostate cancer patients (hormone-sensitive or castration-resistant) in an oligorecurrent stage defined as less than 5 bone or lymph node metastases by Choline PET-CT or/and WB-DWI-MRI, after primary treatment, were assigned to receive ADT and SBRT (Vertebral metastases: 1 × 16-18Gy or 3 × 8-9Gy; lymph node metastases: 3 × 10-11 Gy or 6 × 7,5Gy; non-spinal bone metastases: 1 × 16Gy or 3 × 10Gy). Inclusion criteria included: more than 1 year from primary treatment to biochemical recurrence and PSA doubling time greater than 2 months. A minimum of 24 months of LhRh analogues from the time of the enrollment was required and concomitant treatment with chemotherapy, abiraterone or enzalutamide was not allowed. Oncologic outcomes defined by PCWG3 were evaluated separately for hormone-sensitive and castration-resistant patients, using Kaplan-Meier competing risks, and Cox regression. Toxicity was prospectively evaluated according to CTCAE.v4 criteria. Results From 07/2014 to 12/2019, 81 patients from 14 Spanish centers were recruited with a total of 117 oligometastases treated, 67 in lymph nodes, 43 in non-‐spinal bones and 7 in spinal bones. 14 patients were recruited in a castration-resistance status. Median follow-up was 41 months, (range 18 - 72 months). 13 hormone-sensitive (19,4%) and 8 castration-resistant (57,1%) oligorecurrent patients presented distant disease progression. Median distant progression-free survival (DPFS) was 54,2 months (IC95% = 48,2 – 60,3). 18 of the patients who progressed (85,7%) were treated with SBRT for the new lesions, 7 of them presented a subsequent distant progression (38,9%), with a median of second DPFS of 24,4 months (95% CI = 23,7 – 25,2). In the castration resistant subgroup, median DPFS was 33,5 months (range 14,8 – 52,1), 42,9% of them were free from distant disease progression at last follow-up, without the need to start second generation hormonal treatment. Tolerance and toxicity profiles were excellent, none of the patients developed toxicity ≥G3 or symptoms related to local progression of the disease. Conclusion Combination of SBRT and ADT is a safe treatment approach with favorable clinical outcomes for hormone-sensitive and castration-resistant prostate cancer patients. Validation studies are needed in castration-resistant patients. ClinicalTrials.gov Identifier: NCT02192788

Published
2021

5. MP22-06 IMAGING TARGETED TREATMENTS VERSUS EXTENDED SALVAGE LYMPH NODE DISSECTION FOR PATIENTS WITH A SINGLE NODAL RECURRENCE OF PROSTATE CANCER: A COMPARATIVE ANALYSIS FROM A LARGE MULTI-INSTITUTIONAL SERIES

Author

Alberto Briganti, Christian G. Stief, Giorgio Gandaglia, Thomas Zilli, David Pasquier, R. Jeffrey Karnes, Alfonso Gomez De Iturriaga, Beatrice Detti, Daniar Osmonov, Piet Ost, Nicholas van As, Inderbir S. Gill, Derya Tilki, Fabio Trippa, Alexander Mottrie, Elise De Bleser, Shankar Siva, Steven Joniau, Piet Dirix, Peter Albers, Nicola Fossati, Shahrokh F. Shariat, Barbara Alicja Jereczek-Fossa, Markus Graefen, Francesco Montorsi, Andrei Fodor, Hein Van Poppel, and Axel Heidenreich

Subjects
medicine.medical_specialty, Dissection, Series (stratigraphy), Prostate cancer, medicine.anatomical_structure, business.industry, Urology, medicine, Radiology, business, medicine.disease, NODAL, Lymph node
Abstract

INTRODUCTION AND OBJECTIVES:Extended and targeted treatment approaches have been proposed for patients affected by nodal recurrence of prostate cancer (PCa). However, a significant under-estimation...

Published
2019

6. SP-0031 For the motion rebuttal

Author

A. Gomez de Iturriaga

Subjects
Physics, Classical mechanics, Oncology, Rebuttal, Radiology, Nuclear Medicine and imaging, Hematology, Motion (physics)
Published
2021

7. Phase II Trial of SBRT and Hormone Therapy for Oligometastases in Prostate Cancer

Author

J. Pastor Peidro, A. Gomez de Iturriaga, Aniceto Mendez, C. Ibañez, Francisco J. López, M.L. Vázquez de la Torre, A. S. Garcia Blanco, M.D.M. Puertas, L. A. Perez Romasanta, A. Rodríguez, M. Rico, F. Ferrer, J.J. Valero, M. Porras-Martínez, T. Piquer Camanes, P. Samper Ots, Antonio J. Conde-Moreno, Almudena Zapatero, C. Ferrer, and Asunción Hervás

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, medicine.medical_treatment, medicine.disease, Prostate cancer, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hormone therapy, business
Published
2019

8. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

E. De Bleser, B.A. Jereczek-Fossa, D. Pasquier, T. Zilli, N. Van As, S. Siva, A. Fodor, P. Dirix, A. Gomez De Iturriaga, F. Trippa, B. Detti, G. Ingrosso, L. Triggiani, B. Alessio, F. Alongi, D. Reynders, V. Fonteyne, A. Surgo, K. Loukili, R. Miralbell, P. Silva, S. Chander, E. Goetghebeur, and P. Ost

Subjects
Urology
Published
2019

9. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Reynders, D., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Silva, P., additional, Chander, S., additional, Goetghebeur, E., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

10. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

Author

Piet Ost, Alison Tree, Barbara Alicja Jereczek-Fossa, Filippo Alongi, David Pasquier, S. Pedro, Shankar Siva, K. Loukili, N. Di Muzio, Alessia Surgo, Beatrice Detti, Andrei Fodor, Thomas Zilli, Valérie Fonteyne, N. van As, Raymond Miralbell, Piet Dirix, Fabio Trippa, E. De Bleser, Gianluca Ingrosso, Andrea Lancia, Sarat Chander, Giulio Francolini, B. Alessio, A. Gomez De Iturriaga, and Luca Triggiani

Subjects
Radiation therapy, medicine.medical_specialty, Prostate cancer, business.industry, Urology, medicine.medical_treatment, medicine, Radiology, NODAL, medicine.disease, business, Stereotactic body radiotherapy
Published
2018

11. PO-0849 Pattern of Relapse After Metastases Directed Therapy in Oligorrecurrent Prostate Cancer

Author

D. Büchser, I. San Miguel, J. Garcia Olaverri, Emilia Rodeño, I. Fernandez, Pedro Bilbao, F. Suarez, R. Ortiz de Zarate, Lorea Martinez-Indart, Francisco Casquero, Roberto Llarena, and A. Gomez de Iturriaga

Subjects
Oncology, Prostate cancer, medicine.medical_specialty, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business
Published
2019

12. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Pedro, S., additional, Chander, S., additional, Di Muzio, N.G., additional, Francolini, G., additional, Lancia, A., additional, Tree, A., additional, and Ost, P., additional

Published
2018
Full Text
View/download PDF

13. Survival after Biochemical Failure in Prostate Cancer Treated with Radiation Therapy

Author

González, C., primary, Jove-Teixido, J., additional, Zapatero, A., additional, Pastor Peidro, J., additional, Vázquez de la Torre, M.L., additional, Casana, M., additional, Mengual, J.L., additional, Gomez CaamaNo, A., additional, Gomez De Iturriaga, A., additional, Vallejo, C., additional, Henriquez, I., additional, Muñoz-García, J.L., additional, Clemente Quiles, J., additional, Porras-Martínez, M., additional, Collado, E., additional, Ossola Lentati, G., additional, Villafranca Iturre, E., additional, Cabeza Rodriguez, M.D.L.A., additional, and Lopez-Torrecilla, J., additional

Published
2018
Full Text
View/download PDF

14. Survival after Biochemical Failure in Prostate Cancer Treated with Radiation Therapy

Author

J. L. Mengual, G. Ossola Lentati, E. Collado, Almudena Zapatero, J. López-Torrecilla, J. Pastor Peidro, J.L. Muñoz-García, Cristina Valeria Calderón Vallejo, Celene Gonzalez, M. Casaña, A. Gomez De Iturriaga, M. Porras-Martínez, J. Jove-Teixido, J. Clemente Quiles, E. Villafranca Iturre, M.L. Vázquez de la Torre, Iván Henríquez, M.A. Cabeza Rodriguez, and A. Gómez Caamaño

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Biochemical failure, medicine.medical_treatment, medicine.disease, Radiation therapy, Prostate cancer, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business
Published
2018

15. Pattern of Relapse after Metastases Directed Therapy in Patients with Oligorecurrent Prostate Cancer Detected with Choline PET-CT

Author

I. San Miguel, Pedro Bilbao, D. Büchser, Lorea Martinez-Indart, J. Garcia Olaverri, Emilia Rodeño, F. Suarez, I. Fernandez, R. Ortiz de Zarate, Francisco Casquero, Roberto Llarena, and A. Gomez de Iturriaga

Subjects
Cancer Research, medicine.medical_specialty, Prostate cancer, Radiation, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, In patient, Radiology, Choline pet ct, business, medicine.disease
Published
2018

17. 771 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Reynders, D., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Goetghebeur, E., and Ost, P.

Published
2019
Full Text
View/download PDF

21. EP-1113: Prospective evaluation of factors associated with weight loss in patients undergoing radiotherapy

Author

Francisco Casquero, E. Boveda, A. Gomez de Iturriaga, Pedro Bilbao, Lorea Martinez-Indart, Jon Cacicedo, and O. del Hoyo

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, Prospective evaluation, Surgery, Radiation therapy, Oncology, Radiology Nuclear Medicine and imaging, Weight loss, medicine, Radiology, Nuclear Medicine and imaging, In patient, medicine.symptom, business
Published
2013

22. PO-0941: A prospective analysis of inter and intrafractional errors to calculate CTV to PTV margin in HN cancer patients

Author

Jose Fernando Perez, Jon Cacicedo, F. Caquero, Pedro Bilbao, O. del Hoyo, A. Lasso, R. Ortiz de Zarate, I. Trueba, E. Boveda, and A. Gomez de Iturriaga

Subjects
Prospective analysis, Oncology, business.industry, Radiology Nuclear Medicine and imaging, Medicine, Cancer, Radiology, Nuclear Medicine and imaging, Ptv margin, Hematology, Nuclear medicine, business, medicine.disease
Full Text
View/download PDF

23. P046 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis.

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., and Pedro, S.

Subjects
*CANCER radiotherapy, *PROSTATE cancer, *RADIOISOTOPE brachytherapy, *STEREOTACTIC radiotherapy, *CANCER treatment
Published
2018
Full Text
View/download PDF

24. A prospective analysis of factors that influence weight loss in patients undergoing radiotherapy.

Author

Cacicedo J, Casquero F, Martinez-Indart L, del Hoyo O, Gomez de Iturriaga A, Navarro A, and Bilbao P

Subjects
Body Weight, Head and Neck Neoplasms radiotherapy, Humans, Prospective Studies, Radiotherapy adverse effects, Risk Factors, Neoplasms radiotherapy, Weight Loss
Abstract

Malnutrition occurs frequently in patients with cancer. Indeed, a variety of nutritional and tumor-related factors must be taken into account in these patients. Recognizing this relationship, we aimed to prospectively evaluate the risk factors that influence weight loss in patients undergoing radiotherapy with oral nutritional supplementation and dietetic counseling. Weight loss of 74 patients during radiotherapy and 1 month after treatment was analyzed. Parameters such as age, gender, tumor location, tumor stage, Eastern Cooperative Oncology Group performance status (ECOG PS) score, and the use of chemotherapy were analyzed to evaluate their influence on weight loss. All patients underwent oral nutritional supplementation and dietetic counseling. Forty-six (65.7%) patients lost weight, with a mean weight loss of (4.73 ± 3.91) kg, during radiotherapy. At 1 month after treatment, 45 (66.2%) patients lost weight, presenting a mean weight loss of (4.96 ± 4.04) kg, corresponding to a (6.84 ± 5.24)% net reduction from their baseline weight. Head and neck cancer patients had a mean weight loss of (3.25 ± 5.30) kg, whereas the remaining patients had a mean weight loss of (0.64 ± 2.39) kg (P = 0.028) during radiotherapy. In the multivariate analysis, the head and neck tumor location (P = 0.005), use of chemotherapy (P = 0.011), and ECOG PS score of 2-3 (P = 0.026) were considered independent risk factors. Nutritional status and parameters, such as tumor location (especially the head and neck), the use of chemotherapy, and the ECOG PS score, should be evaluated before radiotherapy because these factors can influence weight loss during radiotherapy and 1 month after treatment.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results